Latest revenue
$14.4M
as of 2026-03-31
Latest net income
$-8.1M
as of 2026-03-31
Net margin
-55.8%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AQST is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $357.4M
- Enterprise value
- $285.4M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $7.55
- 52-wk low
- $2.93
- Beta
- —
- Shares out
- 91.1M
5-year trend
What this company does
Item 1. Business Overview Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. We are advancing our late stage non-device based epinephrine prodrug product candidate for the treatment of severe allergic reactions, including anaphylaxis, under the "Anaphylm™" trade name, and our AdrenaVerse™ epinephrine prodrug pipeline platform. We have four licensed commercialized products which are marketed by our licensees in…
AI summary unavailable — showing raw filing excerpt
Generated from AQST's filing dated 2026-03-04
Key risks
Item 1A. Risk Factors Investing in our common stock involves significant risk and investors should carefully consider the risks described below, together with all other information included or referenced in this Annual Report on Form 10-K. There are numerous and varied risks, known and unknown, that may prevent us from achieving our goals. The risks described below are not the only ones we will face. In addition to the other information in this Annual Report on Form 10-K, any of the factors set forth below could significantly and negatively affect our business, financial condition, results of operations or prospects and the trading price of our stock. This section contains forward-looking…
AI summary unavailable — showing raw filing excerpt
Generated from AQST's filing dated 2026-03-04
Profitability
Operating margin
-159.5%
198.4%Net margin
-188.1%
145.3%Return on equity
139.3%
236.0%Return on assets
-52.2%
20.0%Leverage
Debt / equity
-3.67×
87.8%Long-term debt / equity
-0.46×
49.9%Debt / assets
137.5%
32.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $14.4M | +65.7% | $-8.1M | +64.9% | -55.8% |
Q4 2025 2025-12-31 | $13.0M | +9.7% | $-31.9M | -86.8% | -244.8% |
Q3 2025 2025-09-30 | $12.8M | -5.4% | $-15.4M | -34.2% | -120.6% |
Q2 2025 2025-06-30 | $10.0M | -50.2% | $-13.5M | -393.6% | -135.4% |
Q1 2025 2025-03-31 | $8.7M | -27.7% | $-22.9M | -78.7% | -263.0% |
Q4 2024 2024-12-31 | $11.9M | — | $-17.1M | — | -143.7% |
Q3 2024 2024-09-30 | $13.5M | +4.2% | $-11.5M | -4875.5% | -85.0% |
Q2 2024 2024-06-30 | $20.1M | +51.8% | $-2.7M | -220.6% | -13.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AQST — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$3.4M
Net activity
−$3.4M
Distinct insiders
8
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AQST
Institutional value
$129.5M
Total shares held
32.3M
Distinct holders
101
-72 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Bratton Capital Management, L.P. | 9.8M | $40.7M | +0 (+0.0%) | No change |
| 2 | BlackRock, Inc. | 7.5M | $31.2M | -266.3K (-3.4%) | Trimmed |
| 3 | FEDERATED HERMES, INC. | 2.9M | $12.2M | +907.5K (+44.6%) | Added |
| 4 | Walleye Capital LLC | 1.2M | $4.9M | +882.1K (+306.5%) | Added |
| 5 | COMMONWEALTH EQUITY SERVICES, LLC | 1.1M | $4.5M | +62.9K (+6.2%) | Added |
| 6 | WELLS FARGO & COMPANY/MN | 1.0M | $4.3M | -153.9K (-12.9%) | Trimmed |
| 7 | JANE STREET GROUP, LLC | 1.0M | $4.3M | +517.8K (+101.1%) | Added |
| 8 | WASATCH ADVISORS LP | 878.3K | $3.6M | +197.1K (+28.9%) | Added |
| 9 | BNP PARIBAS FINANCIAL MARKETS | 809.0K | $3.4M | -362.7K (-31.0%) | Trimmed |
| 10 | Everstar Asset Management, LLC | 553.2K | $2.3M | +208.4K (+60.4%) | Added |
| 11 | UBS Group AG | 464.2K | $1.9M | +167.8K (+56.6%) | Added |
| 12 | STIFEL FINANCIAL CORP | 359.9K | $1.5M | -9.8K (-2.7%) | Trimmed |
| 13 | Bank of New York Mellon Corp | 255.2K | $1.1M | -14.6K (-5.4%) | Trimmed |
| 14 | Nuveen, LLC | 253.5K | $1.1M | -110.6K (-30.4%) | Trimmed |
| 15 | Latash Investments, LLC | 243.1K | $1.0M | +0 (+0.0%) | No change |
| 16 | Simplify Asset Management Inc. | 234.3K | $972.3K | — | New |
| 17 | Hudson Bay Capital Management LP | 234.0K | $971.1K | — | New |
| 18 | Russell Investments Group, Ltd. | 226.2K | $938.6K | +16.7K (+8.0%) | Added |
| 19 | Creative Planning | 183.2K | $760.2K | +36.2K (+24.6%) | Added |
| 20 | RHUMBLINE ADVISERS | 136.5K | $566.6K | +3.0K (+2.2%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AQST's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.